Overview

This trial is active, not recruiting.

Condition peripheral arterial disease
Treatment femoropopliteal stenting
Sponsor Veryan Medical Ltd.
Start date February 2010
End date October 2012
Trial size 86 participants
Trial identifier NCT02163863, Mimics

Summary

Primary purpose of the Mimics Study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
femoropopliteal stenting
(Active Comparator)
CR Bard LifeStent System, delivering a self-expanding Nitinol stent
femoropopliteal stenting

Primary Outcomes

Measure
Primary safety endpoint
time frame: 30 days
Primary performance endpoint
time frame: 6 months

Secondary Outcomes

Measure
Acute procedural outcomes
time frame: Within 30 days of the procedure
Post implant anatomical outcomes
time frame: Immediately post implant but within the index procedure
Mechanical outcomes
time frame: 30 days, 6, 12 and 24 months
Haemodynamic outcomes
time frame: discharge, 30 days, 6, 12 and 24 months
Clinical and functional outcomes
time frame: discharge, 30 days, 6, 12 and 24 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - >18 years of age - The subject or legal guardian has been informed of the nature of the study and agrees to its provisions and has provided informed written consent - The subject is willing to be available for the appropriate follow-up for the duration of the study - Rutherford 1-4(mild claudication to ischemic rest pain), with an occlusion or de novo and/or restenotic SFA/PPA lesion ≥50% and ABI/TBI <0.90/0.80 - Single target lesion located at least 1 cm distal to the take-off of the profunda femoris artery and at least 3 cm proximal to the highest point of the cortical margin of the femur - Target vessel reference diameter is ≥3.5 mm and ≤7.0 mm - Target lesion length is ≥4.0 cm and ≤10.0 cm, and must be intended to be covered with one single stent only. A second stent is permitted to be placed only if, in the physician's opinion, the first stent did not achieve an optimum clinical result - Adequate distal run-off to the ankle in the target limb (defined as having at least one patent calf vessel <50% stenosed - Life expectancy >24 months Exclusion Criteria: - Women who do not have a negative serum or urine pregnancy test documented within 7 days prior to enrollment (if not already post menopausal) or women who do not agree to use an adequate birth control method for up to 24 months after Device implantation - An uncontrolled infectious disease - A condition that inhibits radiographic visualisation of the arteries - Any condition that precludes safe access with PTA devices, such as: excessive common femoral artery disease, unresolved fresh thrombus in the target lesion/vessel, or a target lesion/vessel that is excessively tortuous or calcified - Known allergy to, or intolerance of, Nitinol - Known intolerance of aspirin and/or clopidogrel - Known hypersensitivity to contrast media which cannot be pre-treated - Participation in another device or drug study. Subject must have completed the follow- up phase of any previous study at least 30 days prior to enrollment into this study. The subject may only be enrolled in this study once - The subject is unable and/or unwilling to cooperate with study procedures or required follow-up visits - History of bleeding diatheses or coagulopathy or will refuse blood transfusions - Known impaired renal function, defined as creatinine >2.5 mg/dl except subjects under chronic renal replacement therapy - Known platelet count <80,000 cells/mm3 or >700,000 cells/mm3 - Known WBC of <3,000 cells/mm3 - The subject is unable to bend lower limbs (full knee flexion) and/or has a knee prosthesis - Previous treatment of the target lesion 6 months prior to enrollment; previous femoropopliteal bypass in the target vessel; previous stenting of the target lesion - Previous stenting of the SFA, popliteal and tibial arteries within the target limb - Target lesion located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion - Target lesion requires treatment other than standard PTA prior to stent placement (i.e., no other devices or procedures such as cutting balloons and laser atherectomy are permitted to be used during the index procedure) - Lesions in contralateral SFA that require intervention during the index procedure, or within 30 days after the index procedure, unless both limbs are able to be and are included in the study - Multiple lesions in the target vessel that require stenting within 30 days after study procedure - Target lesion length is > 10cm or the physician believes prior to stent placement that the lesion cannot be covered by one single stent - The target lesion is severely calcified

Additional Information

Official title BioMimics 3D Stent Clinical Investigation: The Mimics Study
Principal investigator Thomas Zeller, M.D.
Description The Mimics Study is a prospective, part randomized study; an initial roll-in registry of 10 subjects treated with BioMimics 3D followed by a randomized assignment to treatment with BioMimics 3D or Control on a 2:1 basis for 76 subjects. The primary purpose of the study is to evaluate the safety and performance of the BioMimics 3D Stent System in the treatment of symptomatic SFA/proximal popliteal disease based on: - Safety; measured by freedom from major adverse events determined at 30 days after the procedure, compared to historic controls. - Performance; measured by freedom from clinically driven TLR at 6 months, compared to historic controls.
Trial information was received from ClinicalTrials.gov and was last updated in June 2014.
Information provided to ClinicalTrials.gov by Veryan Medical Ltd..